Search - tctmd.com

Displaying 481 - 500 of 8219

Sort: Relevancy | Date

Presentation TCT 2016

Device Overview and Ongoing Study Design: Boston Scientific REINFORCE

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Ajay J. Kirtane

October 30, 2016

Presentation TCT 2016

Levels of Evidence: Single-center vs Multicenter Trials

Presenter: Peter Juni, E. Magnus Ohman, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Have Contemporary DES Narrowed the Gap With CABG in Multivessel Disease? From BEST to SYNTAX II and Beyond

Presenter: Dean J. Kereiakes, Pieter C. Smits, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Marc Gillinov

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Bryan Williams

October 30, 2016

Presentation TCT 2016

Comparative DES Outcomes: What Have We Learned From the SCAAR Registry? Update on Recent New Generation DES

Presenter: Dean J. Kereiakes, Pieter C. Smits, Stefan K. James

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat

October 30, 2016

Presentation TCT 2016

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

Presenter: Peter Juni, E. Magnus Ohman, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Overcoming RDN Catheter Design Limitations: Issues and Spectrum of Devices

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Horst Sievert

October 30, 2016

Presentation TCT 2016

Comparative DES Outcomes: What Have We Learned From 7 SORT-OUT Trials?

Presenter: Dean J. Kereiakes, Pieter C. Smits, Lisette Okkels Jensen

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies II: Updates From SURTAVI

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Renal Denervation for Hypertension: New Insights and A Progress Report From Last Year

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Felix Mahfoud

October 30, 2016

Presentation TCT 2016

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Presenter: Roxana Mehran, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Orsiro Cobalt Chromium Sirolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Thomas Pilgrim

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: From Nobori to Ultimaster Biolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Shigeru Saito

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Hypertension Treatment Targets Beyond the Kidneys

Presenter: Felix Mahfoud, Michael A. Weber, Atul Pathak

October 30, 2016

Advertisement

Device Overview and Ongoing Study Design: Boston Scientific REINFORCE

Levels of Evidence: Single-center vs Multicenter Trials

Have Contemporary DES Narrowed the Gap With CABG in Multivessel Disease? From BEST to SYNTAX II and Beyond

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Comparative DES Outcomes: What Have We Learned From the SCAAR Registry? Update on Recent New Generation DES

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

Overcoming RDN Catheter Design Limitations: Issues and Spectrum of Devices

Comparative DES Outcomes: What Have We Learned From 7 SORT-OUT Trials?

Intermediate-Risk Studies II: Updates From SURTAVI

Renal Denervation for Hypertension: New Insights and A Progress Report From Last Year

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Stent Design and Comprehensive Data Review: Orsiro Cobalt Chromium Sirolimus-Eluting Stents

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Stent Design and Comprehensive Data Review: From Nobori to Ultimaster Biolimus-Eluting Stents

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Hypertension Treatment Targets Beyond the Kidneys

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content